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Effects of Gastric Bypass and Gastric Banding 
on Glucose Kinetics and Gut Hormone Release
Frédérique Rodieux1,2, Vittorio Giusti2, David A. D’Alessio3, Michel Suter4 and Luc Tappy1,2
Background: Bariatric surgery markedly improves glucose homeostasis in patients with type 2 diabetes even before 
any significant weight loss is achieved. Procedures that involve bypassing the proximal small bowel, such as Roux-en-Y 
gastric bypass (RYGBP), are more efficient than gastric restriction procedures such as gastric banding (GB).
Objective: To evaluate the effects of RYGBP and GB on postprandial glucose kinetics and gastro-intestinal hormone 
secretion after an oral glucose load.
Methods and Procedures: This study was a cross-sectional comparison among non-diabetic, weight-stable women 
who had undergone RYGBP (n = 8) between 9 and 48 months earlier or GB (n = 6) from 25 to 85 months earlier, and 
weight- and age-matched control subjects (n = 8). The women were studied over 4 h following ingestion of an oral 
glucose load. Total glucose and meal glucose kinetics were assessed using glucose tracers and plasma insulin, and 
gut hormone concentrations were simultaneously monitored.
Results: Patients who had undergone RYGBP showed a a more rapid appearance of exogenous glucose in the 
systemic circulation and a shorter duration of postprandial hyperglycemia than patients who had undergone GB 
and C. The response in RYGBP patients was characterized by early and accentuated insulin response, enhanced 
postprandial levels of glucagon-like peptide-1 (GLP-1) and polypeptide YY (PYY), and greater postprandial 
suppression of ghrelin.
Discussion: These findings indicate that RYGBP is associated with alterations in glucose kinetics and glucoregulatory 
hormone secretion. These alterations are probably secondary to the anatomic rearrangement of the foregut, given the 
fact that they are not observed after GB. Increased PYY and GLP-1 concentrations and enhanced ghrelin suppression 
are compatible with reduced food intake after RYGBP.
Obesity (2008) 16, 298–305. doi:10.1038/oby.2007.83
IntroductIon
Recent studies have shown that bariatric surgery is not only 
highly efficient in promoting weight loss, but that it also leads 
to an improvement, or resolution of, most of the obesity- related 
co-morbidities (1–3). In particular, patients with diabetes mel-
litus show a marked improvement in glucose homeostasis after 
undergoing surgery for weight loss (4–9). In fact, most of the 
bariatric procedures commonly used worldwide have been 
shown to restore a normal glucose profile in many diabetes 
patients. However, meta-analysis suggests that procedures that 
involve bypassing the proximal small bowel, such as Roux-
en-Y gastric bypass (RYGBP) and biliopancreatic diversion 
are more efficient than procedures involving gastric restriction 
only, such as gastric banding (GB) (1,3,10). On the basis of cur-
rent reports, 80–100% of diabetes patients have normal glyce-
mia after RYGBP and biliopancreatic diversion vs. 30–70% of 
patients after GB. Importantly, several studies have shown that 
the blood glucose profile is improved very early after surgery, 
long before any significant weight loss or fat reduction occurs 
(11–13), thereby indicating that weight loss (and, presumably, 
improved insulin sensitivity) is not the sole factor involved in 
achieving an improved glucose profile. However, the mecha-
nisms whereby bariatric surgery improves glucose metabolism 
are not fully understood. Several recent reports indicate that 
gut hormone release is significantly altered after bypass of the 
proximal small bowel, secondary to exclusion of food from the 
intestinal transit (14,15). The ensuing pattern of gut hormone 
secretion may contribute not only to reduction in food intake 
but also to stimulation of insulin secretion (16–18). In addition, 
by altering gastric size and mobility, gastric surgery may signifi-
cantly impact postprandial glucose absorption and kinetics.
In order to better understand the effects of bariatric surgery 
on glucose regulation we compared the effects of RYGBP and 
GB on postprandial glucose kinetics. For this purpose, we 
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studied two groups of non-diabetic patients who had under-
gone successful RYGBP or GB some months to years earlier, 
and one group of weight-matched non-diabetic control sub-
jects (C). In order to avoid the interference effects of negative 
energy balance, we studied the patients after their period of 
most rapid weight loss, when their body weights were stable. 
Exogenous glucose appearance (EGA) and endogenous glu-
cose production were assessed using a dual glucose isotope 
method after a standardized glucose load. Plasma glucoregula-
tory hormone and gut hormone concentrations were simulta-
neously monitored.
Methods And Procedures
subjects
Three groups of female subjects were recruited to participate in this 
study: (i) patients who had undergone RYGBP (n = 8), (ii) patients 
who had undergone GB (n = 6), and (iii) non-operated control sub-
jects (n = 8). The criteria for inclusion in the first two groups (post-
surgery) were that the subjects had undergone the surgical procedure 
>9 months previously, had maintained a stable body weight (with 
weight variation <2 kg) for the past 3 months, and had no diabetes mel-
litus or impaired glucose tolerance before surgery. The interval between 
surgery and metabolic evaluation was 9–48 months in patients who had 
undergone RYGBP, and 25–85 months in patients who had undergone 
GB. Preoperative weight (RYGBP: 122.3 ± 8.9 kg, GB: 109.3 ± 2.1 kg, 
P = NS) and BMI (RYGBP: 44.9 ± 1.8 kg/m2, GB: 41.1 ± 0.5 kg/m2, P < 
0.05), and weight loss after surgery (RYGBP: 47.8 ± 3.3 kg, GB: 32.4 ± 
2.0 kg, P < 0.01) were all higher after RYGBP. The eight control subjects 
were recruited by advertisement, and were weight-matched to post-
surgery RYGBP and GB patients. All the subjects were white women, 
with ages ranging from18–50 years. None of the subjects were receiv-
ing any medication and, except for obesity, there were no remarkable 
findings from their physical examination. Body composition was meas-
ured using bioimpedancemetry (Bioscan 920, Maltron International, 
Rayleigh, Essex). The anthropometric characteristics of the three 
groups of subjects are shown in Table 1. Each subject gave her writ-
ten informed consent to the study after being informed of its nature, 
purpose, and potential risks, both verbally and in writing. The protocol 
was approved by the ethical committee of Lausanne University Faculty 
of Biology and Medicine.
experimental protocol
At inclusion, the weights and heights of the subjects were measured, 
body composition was assessed, and resting energy expenditure was 
determined by indirect calorimetry during 60 min in the fasting state. 
The subjects were then instructed to follow a standardized isocaloric 
diet (50% carbohydrate, 35% fat, and 15% protein), and to avoid vig-
orous physical activity and caffeine- and alcohol-containing drinks 
the day before the test. The experiments began in the morning after a 
10-h overnight fast. Upon arrival at the metabolic investigation unit, 
the subjects were asked to empty their bladders. Urine was collected 
at the end of the experiment to determine urinary nitrogen excretion 
rates. For collecting arterialized venous blood, a retrograde catheter 
was inserted in a vein in the dorsum of the hand, warmed in a ther-
mostabilized box heated to 50 °C. Another catheter was inserted in 
a forearm vein of the contralateral arm for infusing 6,6 2H2 glucose. After a 2-h period to allow for tracer equilibration, an oral U 13C-
labeled glucose load was administrated (0.5 g/kg body weight, 2% 
enriched with 13C glucose). Time 0 was taken as the time immediately 
preceding the glucose ingestion. After the ingestion and over a time 
period of 4 h, the rate of the 6,6 2H2 glucose infusion was adjusted to the expected rate of glucose appearance (20 μg/kg/min during the 
first 2 h, followed by rates of 30, 40, 30, and 20 μg/kg/min during each 
60-min period thereafter).
Blood samples were collected at time points −120, −30, and 0 min 
for determining basal glucose production and basal hormone (insulin, 
ghrelin, polypeptide YY (PYY), gastric inhibitory polypeptide (GIP), 
 glucagon-like peptide-1 (GLP-1)) and concentrations of substrates (gly-
cemia, free fatty acids (FFA), etc.), and then at time points 15, 30, 45, 60, 
90, and every 30 min so as to determine plasma glucose isotopic enrich-
ments and concentrations of hormones and substrates. The samples 
were immediately centrifuged at 4 °C. Plasma was collected and stored 
at −20 °C until analysis. Respiratory gas exchanges were continuously 
monitored by open circuit indirect calorimetry (Datex, France).
Analytical procedures
Immediately after blood was drawn, plasma was separated by centrifu-
gation at 4 °C for 10 min at 3,600 r.p.m. and stored at −20 °C. Plasma glu-
cose was measured by the glucose oxydase method, using a Beckman 
Glucose Analyzer II (Beckman Instruments, Fullerton, CA). Plasma 
concentrations of insulin, total ghrelin, total GLP-1, and total human 
PYY were determined by radioimmunoassay using specific kits (Linco 
Research, St. Charles, MO). Total GIP was determined by an enzyme-
linked immunosorbent assay on unextracted plasma, using a specific 
kit from Linco Research (St. Charles, MO). FFA concentrations were 
analyzed using an enzymatic and colorimetric method (kit from Wako 
Chemicals, Neuss, Germany). Plasma 6,6 2H2 glucose and plasma U 
13C glucose isotopic enrichments were measured using gas chromato-
graphy mass spectrometry (GC 5890/MS5971; Hewlett-Packard, Palo 
Alto, CA), as previously described (19).
calculations
The rate of glucose appearance (GRa) and the rate of glucose disappea-
rance (GRd) were calculated from plasma 6,6 2H2 glucose enrichments 
according to Steele’s equation for non-steady state, using a pool fraction 
of 0.75 and a distribution volume of 0.2 l/kg (20–22). The rate of EGA 
was calculated from plasma U 13C enrichments using the method of 
Steele et al. (23). Hepatic glucose output was calculated as the difference 
between total glucose appearance and EGA.
Net glucose oxidation rates were estimated from gas exchange meas-
urements, using the equations of Livesey and Elia (24,25). The net oxida-
tion rate obtained corresponds to oxidation of endogenous glycogen in 
the fasting condition, and to oxidation of both endogenous glycogen and 
exogenous glucose after ingestion of glucose.
statistical analysis
All data in the text, tables, and figures are expressed as mean values ± 
s.e.m. The areas under the curve were calculated using trapezoidal 
rules. Inter-group comparisons were made using ANOVA, corrected 
for multiple comparisons with post-hoc group comparisons using the 
Fisher test. We used the non-parametric test of Kruskal–Wallis for data 
that did not follow normal distribution. A P value <0.05 was considered 
to be statistically significant.
results
characteristics of study groups
Table 1 shows the characteristics of the subjects of each of 
the three groups. There were no significant differences in age, 
weight, BMI, and body composition between the three groups at 
inclusion, but preoperative weight and BMI, and postoperative 
weight loss were higher in patients who had undergone RYGBP. 
All the subjects had been maintaining a stable weight for at least 
3 months and were tested under the same conditions. Subjects 
who had undergone a GB procedure had a longer time interval 
between surgery and testing as compared to subjects who had 
undergone RYGBP (P < 0.05), because the former procedure 
has not been performed in our institution since April 2005.
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Glucose, insulin and FFA
Fasting glucose concentrations showed similar values in the 
three groups (RYGBP: 4.5 ± 0.2 mmol/l, GB: 4.7 ± 0.1 mmol/l, 
C: 5.0 ± 0.2 mmol/l; P = NS). As shown in Figure 1a, after the 
oral glucose load, there was a significantly earlier (P < 0.01) and 
exaggerated (P = 0.0001) rise in blood glucose in the RYGBP 
group as compared to the two other groups, with peak glycemia 
occurring at 45 min. Plasma glucose also returned to baseline 
significantly earlier in this group (P = 0.0001). Incremental areas 
under the curve (AUC) (RYGBP: 279.8 ± 44.0 mmol/l/min, GB: 
348.0 ± 14.5 mmol/l/min, C: 336.6 ± 37.7 mmol/l/min, P = NS) 
were not significantly different among the three groups.
Patients who had undergone bariatric surgery (either RYGBP 
and GB) had significantly lower fasting insulin levels as com-
pared to C participants (RYGBP: 45.8 ± 4.2 pmol/l, GB: 50.1 ± 
4.6 pmol/l, C: 86.2 ± 14.3 pmol/l; C vs. RYGBP: P < 0.05; C vs. 
GB: P < 0.05). The RYGBP group exhibited an earlier and higher 
peak insulin response (P < 0.01) with a more rapid return to 
baseline as compared to the other two groups (Figure 1b). 
Total insulin secretion in response to the oral glucose load, as 
assessed by incremental AUC, was lower in the two bariatric 
surgery groups (RYGBP: 29,330.4 ± 3,568.8 pmol min/l, GB: 
28,863.0 ± 6,736.3 pmol min/l, C: 43,426.1 ± 5,387.5 pmol min/l; 
RYGBP vs. C: P < 0.05; GB vs. C: P = 0.051). No significant dif-
ference was observed among the three groups as regards the 
fasting FFA (RYGBP: 672 ± 73 µmol/l, GB: 668 ± 54 µmol/l, 
C: 638 ± 48 µmol/l; P = NS). FFA concentrations after the meal 
were a mirror image of the glucose and insulin excursions; FFA 
showed an earlier decrease after the glucose ingestion in the 
RYGBP patients (Figure 1c).
Glucose kinetics
The time course of U 13C-labeled glucose appearance (Figure 2a) 
paralleled the plasma glucose curve and accounted for the gly-
cemic excursion. In the RYGBP group, EGA in the systemic 
circulation was accelerated (P < 0.005), consistent with more 
rapid absorption of the glucose meal by participants in this 
group. In addition, U 13C-labeled glucose returned to baseline 
more rapidly in this group, indicating a more rapid disposition 
of ingested glucose. However, no difference was observed 
among the three groups in the total EGA over the 4 h follow-
ing the ingestion, as assessed by total AUC of EGA (RYGBP: 
392.8 ± 12.3 mg/kg, GB: 367.3 ± 13.6 mg/kg, C: 383.1 ± 19.4 mg/
kg; P =  NS), thereby indicating similar absorption efficiencies 
of the glucose meal in all the groups. This represented 78.5% of 
the glucose load in the RYGBP group, 73.5% in the GB group, 
and 76.6% in the C group.
Hepatic glucose output (Figure 2b) was promptly inhib-
ited after the ingestion of glucose in the three groups. This 
inhibition occurred earlier (P < 0.05) but was shorter-lived 
in the RYGBP group as compared to the other two groups. 
Basal  levels of (Gra) and GRd were similar in the three groups 
(RYGBP: 1.9 ± 0.3 mg/kg/min, GB: 1.6 ± 0.2 mg/kg/min, 
C: 1.4 ± 0.2 mg/kg/min; P = NS for GRa and RYGBP: 1.9 ± 
0.3 mg/kg/min, GB: 1.7 ± 0.3 mg/kg/min, C: 1.3 ± 0.1 mg/kg/
min; P = NS for Grd). Total glucose appearance was predomi-
nant in the first 60 min in the RYGBP group (Figure 2c), but 
was the same in the three groups during the 4 h following the 
ingestion (RYGBP: 203.8 ± 22.8 mg/kg, GB: 137.8 ± 34.1 mg/
kg, C: 181.5 ± 29.9 mg/kg; P = NS). The GRd (Figure 2c) 
table 1 subjects characteristics
Control  
(n = 8)
RYGBP  
(n = 8)
GB  
(n = 6) P
Age (years) 34.4 ± 3.8 34.0 ± 3.5 39.0 ± 3.0 NS
No. of months 
postoperative
26.7 ± 5.0 57.5 ± 9.1 0.014
Preoperative BMI 44.9 ± 1.8 41.1 ± 0.5 0.015
Postoperative 
weight loss
47.8 ± 3.3 32.4 ± 2.0 <0.01
Postoperative 
weight (kg)
79.3 ± 3.0 73.0 ± 6.4 76.4 ± 2.4 NS
Postoperative BMI 
(kg/m2)
29.2 ± 0.8 27.1 ± 1.5 28.9 ± 0.8 NS
Free fat mass (%) 64.8 ± 3.2 70.3 ± 2.6 62.3 ± 0.7 NS
Fat mass (%) 35.2 ± 3.2 29.7 ± 2.6 37.7 ± 0.7 NS
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Figure 1 Time course of (a) plasma glucose, (b) insulin, and (c) free 
fatty acids. *P ≤ 0.05, RYGBP vs. GB and C. ¤P ≤ 0.05, RYGBP vs. C; 
§P ≤ 0.05, RYGBP and GB vs. C. GB, gastric banding; RYGBP, Roux-
en-Y gastric bypass.
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showed an increase and return to baseline earlier after the glu-
cose ingestion in the RYGBP patients, but glucose disappear-
ance during the 4 h was similar in the three groups (RYGBP: 
214.8 ± 28.2 mg/kg, GB: 119.5 ± 48.7 mg/kg, C: 209.2 ± 
32.6 mg/kg; P = NS). Fasting glucose clearance, as assessed 
by GRd divided by glucose concentration (GRd/glucose) was 
significantly different between RYGBP and C (RYGBP: 0.39 ± 
0.03 mg/kg/min/mmol/l, GB: 0.36 ± 0.06 mg/kg/min/mmol/l, 
C: 0.27 ± 0.03 mg/kg/min/mmol/l; RYGBP vs. C: P < 0.05).
energy expenditure and substrate oxidation
There was no significant difference among the three groups in 
either basal energy expenditure integrated from −60 to 0 min 
(RYGBP: 53.1 ± 3.6 kcal/min, GB: 48.3 ± 1.9 kcal/min, C: 
48.9 ± 2.0 kcal/min; P = NS) or postprandial energy expendi-
ture integrated from 30 to 240 min (RYGBP: 192.0 ± 13.6 kcal/
min, GB: 170.5 ± 6.8 kcal/min, C: 176.3 ± 10.29 kcal/min, 
P = NS) (Figure 3a). Figure 3b,c show the glucose oxidation 
(Gox) and lipid oxidation (Lox) rates respectively, in the three 
groups of subjects. In the RYGBP group the glucose oxidation 
rate increased significantly at an earlier time point than in the 
other two groups, but net glucose oxidation over the course 
of the study was approximately equal in the three groups 
(RYGBP: 349 ± 73 mg/kg, GB: 321 ± 54 mg/kg, C: 390 ± 23 mg/
kg, P = NS). In consonance with the changes in Gox rates, Lox 
showed an earlier decrease after glucose ingestion in the case 
of the RYGBP group.
Gut hormone secretion
There was no significant difference among the three groups in 
fasting ghrelin levels (RYGBP: 274 ± 76 pmol/l vs. GB: 430 ± 
119 pmol/l and C: 343 ± 54 pmol/l, P = NS). In response to 
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Figure 2 Time course of (a) exogenous glucose appearance (EGA),  
(b) hepatic glucose output (HGO), (c) glucose rate of appearance (GRa) 
and (d) glucose rate of disappearance (GRd). *P ≤ 0.05, RYGBP vs. GB 
and C; §P ≤ 0.05, RYGBP and GB vs. C; †P ≤ 0.05, RYGBP vs. GB. GB, 
gastric banding; RYGBP, Roux-en-Y gastric bypass.
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Figure 3 Time course of (a) energy expenditure (EE), (b) glucose 
oxidation (Gox) and (c) lipid oxidation (Lox). ¤P ≤ 0.05, RYGBP vs. GB; 
P ≤ 0.05, RYGBP vs. GB and C. GB, gastric banding; RYGBP, Roux-
en-Y gastric bypass. 
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the oral glucose load, ghrelin levels fell in all groups reach-
ing a nadir at 60 min (Figure 4a). The maximal postprandial 
suppression was significantly greater in the RYGBP group 
than in the the GB and C groups (−27.2% vs. −11.4 and 
−14.8% respectively; P < 0.0005). Fasting PYY was higher 
in the RYGBP subjects (RYGBP: 37 ± 5 pmol/l vs. GB: 23 ± 
2 pmol/l and C: 25 ± 2 pmol/l, RYGBP vs. C: P < 0.05), and 
the integrated PYY response to the oral glucose load was sig-
nificantly enhanced in the RYGBP group as compared to the 
C and GB groups (RYGBP: 3,220 ± 1,243 pmol/l/min, GB: 
201 ± 179 pmol/l/min, C: −243 ± 252 pmol/l/min; RYGBP 
vs. GB: P < 0.05, RYGBP vs. C: P < 0.05) (Figure 4b). There 
was no significant difference among the three groups in 
fasting GLP-1 levels (RYGBP: 7.9 ± 1.9 pmol/l vs. GB: 9.2 ± 
2.3 pmol/l and C: 8.7 ± 2.8 pmol/l; P = NS). Patients with 
RYGBP had an exaggerated GLP-1 response to the oral glu-
cose load (Figure 4c). The increase was >1,000% after 30 min 
in the RYGBP group, as compared to 138 and 162%, respec-
tively, for the GB and C groups (P < 0.005). Postprandial 
GLP-1 secretion, as assessed by incremental AUC, was not 
significantly different among the three groups, but showed 
a trend toward an increase in the RYGBP group (RYGBP: 
2,585 ± 489 pmol/l/min vs. GB: 1,203 ± 282 pmol/l/min and 
C: 1,261 ± 282 pmol/l/min, RYGBP vs. GB: P = 0.062, RYGBP 
vs. C: P = 0.060). Fasting GIP levels were similar in the three 
groups (RYGBP: 39.9 ± 10.6 pmol/l vs. GB: 25.8 ± 7.8 pmol/l 
and C: 21.5 ± 5.8 pmol/l; P = NS). After oral glucose ingestion 
GIP increased in the three groups, with a peak after 30 min 
(Figure 4d). The maximal concentration was not statistically 
different among the three groups (RYGBP: 163 ± 23.4 pmol/l 
vs. GB: 133.4 ± 11.1 pmol/l and C: 167.1 ± 28.7 pmol/l; P = 
NS). But the GIP postprandial response was short-lived (P < 
0.0001) and total postprandial GIP secretion over the 4 h fol-
lowing the ingestion, as assessed by incremental AUC, was 
significantly reduced in the RYGBP group (RYGBP: 3,083.3 ± 
1,258.7 pmol/ml/min, GB: 13,641.5 ± 799.4 pmol/ml/min, 
C: 18,374.5 ± 2,716.3 pmol/ml/min; RYGBP vs. C: P < 0.05).
dIscussIon
A number of studies have reported an impressive and early 
improvement in glucose homeostasis in obese diabetes patients 
after bariatric surgery (4–13), but the mechanisms remain 
controversial. The primary aim of our study was to document 
the consequences of gastric surgery on postprandial glucose 
kinetics. Our results indicate that the rate of exogenous glucose 
absorption into the systemic circulation is markedly increased 
after RYGBP. This is reflected in the more rapid appearance of 
the tracer (added to the glucose meal) into the systemic cir-
culation, and in the rapid postprandial rise in glycemia. This 
finding most likely reflects a rapid emptying rate from the 
gastric remnant. Although, to our knowledge, the rate of the 
emptying of nutrients from the gastric pouch has not been spe-
cifically assessed after RYGBP, there is ample evidence that it is 
accelerated after gastrectomy with Roux-en-Y loops in treating 
for cancer and gastric ulcers (26). We observed no episode of 
hypoglycemia amongst participants in this study. Such rapid 
delivery into the foregut may nonetheless play a role in the 
development of postprandial hypoglycemia or dumping syn-
dromes in susceptible individuals (27–29).
As a result of the early rise in glycemia, plasma insulin con-
centrations increased earlier and reached much higher values 
in the RYGBP group than in the  GB and C groups. In conjunc-
tion with this brisk insulin secretion, total glucose utilization 
was stimulated both earlier and to a greater extent, while sup-
pression of endogenous glucose production was more rapid, 
but shorter-lived in the RYGBP group. In addition, the hyper-
glycemia observed in the RYGBP group may further stimulate 
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Figure 4 Time course of (a) plasma ghrelin, (b) polypeptide YY 
(PYY), (c) glucagon-like peptide-1 (GLP-1), and (d) gastric inhibitory 
polypeptide (GIP), expressed as a percentage of the initial value.  
*P ≤ 0.05, RYGBP vs. GB and C; ¤P ≤ 0.05, RYGBP vs. C. GB, gastric 
banding; RYGBP, Roux-en-Y gastric bypass. 
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glucose utilization through an enhanced glucose-mediated 
glucose disposal.
The proportion of exogenous glucose appearing in the sys-
temic circulation during the 4 h following the ingestion was 
similar in the RYGBP, GB, and  C groups. Approximately 75% 
of the oral load was found in the systemic circulation in each 
group, with the remaining 25% probably accounted for by 
first-pass splanchnic glucose uptake (30). On the basis of these 
results it seems unlikely that there is significant glucose malab-
sorption following RYGBP.
The two surgical procedures appear to affect the glucose–
insulin relationship significantly, although in different ways. 
RYGBP was shown to result in rapid increases in plasma insu-
lin and glucose concentrations, followed by a rapid decrease 
and return to baseline values. When compared to the C group, 
the 4-h AUC for glucose was not altered in the RYGBP group, 
but AUC for insulin was lower. In contrast, in subjects who had 
undergone GB, the increase in plasma insulin showed the same 
time course as in the C group, but the increase was of a lower 
magnitude. This lower insulin response occurred in spite of an 
EGA rate and plasma glucose concentration values similar to 
those observed in C. Interestingly, the overall postprandial rise 
in plasma insulin, assessed as the incremental insulin AUC, 
tended to be reduced in the two bariatric surgery groups. Given 
that insulin AUC reflects insulin secretion, this suggests that 
the insulin requirement per unit of glucose ingested or appear-
ing into the systemic circulation decreased after both RYGBP 
and GB. Our results may therefore indicate enhanced insulin 
sensitivity after bariatric surgery, but they do not indicate a dif-
ferential effect for RYGBP vs. GB. However, the time courses 
of the plasma glycemic and insulin responses suggest that the 
mechanisms responsible for the lower insulin requirement are 
likely to be different post-GB and post-RYGBP. Future studies 
are required for quantitative evaluation of insulin sensitivity in 
such patients.
A major consequence of RYGBP is to divert nutrients away 
from the duodenum and deliver them directly to the more dis-
tal small bowel and the colon. This has important consequences 
for gastro-intestinal hormone secretion, which may be directly 
relevant to glucose homeostasis. An enhancement of the 
GLP-1 response was observed, and has already been reported 
in previous studies of patients with RYGBP (12,31–33) and in 
rats after RYGBP or ileal transposition (34,35). Early stimu-
lation of GLP-1–secreting L-cells, located in the distal small 
bowel and colon, is most probably responsible for this effect. 
The increased levels of PYY  secreted from L-cells (36) have 
also been reported in several other studies (31,33,37), thereby 
adding further support for arriving at this conclusion. On the 
other hand, we (and other researchers as well) (12,39) have 
observed that GIP, which is secreted by endocrine cells located 
in the proximal small bowel (40), reached lower levels post-
prandially and returned to basal concentrations more quickly 
in the RYGBP group of subjects.
It appears, therefore, that more direct delivery of nutrients to 
the distal small bowel favors early and enhanced secretion of 
GLP-1 after gastric bypass, and that this finding may be closely 
related to the effects of RYGBP on glucose homeostasis. One 
study, however, reported that RYGBP enhances GLP-1 secre-
tion in patients with normal glucose tolerance and also in 
patients with impaired glucose tolerance, but not in patients 
with type 2 diabetes mellitus, although it improved glucose tol-
erance in all three groups (32). Another study failed to observe 
an increase in GLP-1 secretion after RYGBP, although glucose 
homeostasis improved after surgery (33). It is unclear why these 
two studies have thrown up conflicting results, but the cause 
may be related to differences in the assays used, differences in 
sample size, or the particular characteristics of the subjects. 
While the bulk of published information suggests that RYGBP 
causes increased postoperative secretion of GLP-1, there may 
be important variations among patients.
The effects of gastric surgery on ghrelin secretion are still 
poorly understood. It has been reported that RYGBP leads to 
a decrease in ghrelin levels early after surgery (18,33,41–44). 
However, since this initial observation, several reports have 
documented that basal ghrelin concentrations are only mini-
mally affected several weeks/months after RYGBP (37,45–48). 
Our present observation further indicates that postprandial 
suppression of ghrelin was enhanced after RYGBP. Because 
ghrelin is produced mainly by cells located in the gastric 
fundus (49), this is consistent with the concept that the post-
prandial suppression of ghrelin secretion does not require the 
contact of food with the fundus of the stomach (50). It has 
been shown previously that plasma insulin is involved in the 
control of ghrelin secretion (51–56), and that plasma levels of 
ghrelin are reduced by insulin, possibly through the hypotha-
lamus–stomach neural pathway (57). The higher postprandial 
suppression of ghrelin secretion after RYGBP could therefore 
be explained by the earlier and higher postprandial increase in 
plasma insulin level.
This study has some important limitations. First, it included 
only obese subjects who had no diabetes before surgery. The 
observations from the study, therefore, depict the effects of 
bariatric surgery per se on glucose kinetics and homeostasis. 
It nonetheless remains possible that some, yet unidentified, 
defects present in obese diabetes patients may be corrected 
by gastric surgery. Second, all studies were done following 
ingestion of a liquid glucose meal. It is therefore quite possible 
that different effects would have been observed after a solid 
mixed meal. This may be particularly true for gastric empty-
ing in patients with GB. Third, postoperative weight loss, and 
the delay between surgery and the metabolic study, were dif-
ferent in patients who had undergone RYGBP and those who 
had undergone GB, and we cannot exclude the hypothesis that 
these factors impact on glucose homeostasis. Fourth, the study 
population was comprised exclusively of women; we assume 
these results will hold good for men as well, but that will 
require direct confirmation from future studies.
In summary, our present results indicate that RYGBP leads to 
marked changes in glucose kinetics after a liquid glucose meal, 
with an early appearance of exogenous glucose into the systemic 
circulation and a rapid clearance of glucose. The AUC for insulin 
was lowered in both RYGBP and GB patients after a glucose meal, 
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thereby suggesting that insulin requirements are decreased after 
these two procedures. Patients who had undergone RYGBP had 
increased postprandial PYY secretion and enhanced suppres-
sion of ghrelin, and this may contribute to reduce food intake. 
RYGBP leads to increased postprandial GLP-1 response, which 
may contribute to reduction in food intake and also to increase 
in postprandial insulin secretion, thereby playing a role in the 
restoration of glycemic control. These observations support the 
contention that a major part of the mechanism by which RYGBP 
causes weight loss and improvements in glucose metabolism is 
mediated by GI hormones.
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